INTRODUCTION
Colorectal cancer (CRC) is a major cause of mortality and morbidity in Europe and worldwide, with an estimated European incidence of 43.5 per 100,000 head of population in 2012 and mortality of 19.5 per 100,000 [1] . UK lifetime risk lies at 1 in 15 for men or 1 in 19 for women [2] , with a similar incidence in Europe [1] ; this incidence is increasing. Colorectal cancer predominantly a ects men and women over the age of 75 and is one of the major causes of cancer death, with a 50.7% 5 year mortality rate [3] .
ere is evidence for a strong genetic component in many cancers, yet more than 90% of CRCs are sporadic, developing from adenomatous polyps over a 10-to 15-year period, through an adenoma-carcinoma sequence, which is likely to be similar to that hypothesised by Vogelstein [4] . e hypothesis identi es a multi-step process of neoplastic change, from an abnormal crypt focus to adenomatous change to frank malignancy. e pathological model has become increasingly re ned since rst suggested over 25 years ago, with clearly associated clusters of mutations at each step, such as APC and k-ras [5] . One might argue that the major consideration in improving the management of CRC is the potential for early diagnosis. A comparison of 5-year survival rates from Duke's staging of CRC (A, the most super cial, 93.2%, compared with C 47.7% and D, distant metastatic spread, 6.6%) [3] clearly demonstrates the potential value of a proactive approach. e existence of precancerous lesions, which can be readily identi ed and removed during a single colonoscopy procedure in the majority of cases [6] gives a powerful argument for a screening programme directed at the most susceptible members of the population. initial test, and recommend that colonoscopy should remain the gold standard [7, 8] . ey provide a synthesis of evidence to support member states in maintaining or establishing such a programme [9] . is re ects the heterogeneous combination of national/regional programmes and non-population based screening found in many European nations, as identi ed in a recently published assessment by Altobelli et al [8] . Many national screening guidelines are available, including FOBt, colonoscopy, exible sigmoidoscopy (FS), CT colonography (CTC), faecal DNA testing and double contrast barium enemas [7, [10] [11] [12] [13] [14] [15] [16] .
CURRENT PRACTICE
Screening for CRC in the UK is currently performed using biennnial non-rehydrated guaiac-based faecal occult blood tests (FOBt: Hema-screen; Immunostics Inc., Ocean, New Jersey, USA) and colonoscopy; a scheme proven to reduce CRC-related mortality [17, 18] . A Cochrane systematic review demonstrated a 16% relative risk reduction from four large studies using the above technique [18] , while the coste ciency of such an approach has been well-established over endoscopy alone [19, 20] . Two forms of FOBt (immunological e.g. OC-Sensor and guaiac e.g. Hemoccult-II) are currently available and used for screening purposes worldwide. However there are several potential pitfalls with this approach: those associated with the uptake and acceptability of such tests by the public, concerns over the sensitivity and speci city of FOBt and endoscopy, the small but signi cant risk of complications associated with the endoscopic procedure itself and, nally, the economic burden of an extensive lower gastrointestinal endoscopy service.
UPTAKE AND ACCEPTABILITY OF FAECAL OCCULT BLOOD TESTING BY THE PUBLIC
e success of any screening programme depends upon the acceptability and uptake of the tests by the public. A review of the rst 6 years of the UK Bowel Cancer Screening Programme (BCSP) described an uptake rate of 55.35% in the over 16 million invitees, from June 2006 to the end of 2012: 88% in the incident round and 45% in prevalent rounds [2] . Of the returned kits, 2.08% proved to be FOBt positive, 90.49% of those with positive kits underwent investigation, of which 84% involved colonoscopy [2] . is suggests that the "rate limiting step" for screening uptake lies in the faecal test itself or public awareness of the importance of CRC screening, especially as uptake for cervical and breast cancer screening in the UK has been measured at 82% and 73% respectively over a similar period [21, 22] . A series of studies have identi ed that acceptability is partly determined by the practicalities of collection, transport and storage of the stool, together with perceptions of the endoscopy test associated with a positive sample and, most notably, an understanding of the nature and purpose of the screening programme [23] [24] [25] .
Guaiac-based FOBts, such as that used in the UK, requires two collections of small amounts of faecal matter from three successive separate motions. No dietary restrictions are required [2] . An unclear test (one to four positive samples out of the six provided) requires a further test to be performed and, if any samples are positive, referral is made for endoscopy. If none are positive, a nal test is sent under the same inclusion criteria [2] . Immunological tests, such as that used in Italy [26] , usually require one collection from three consecutive motions.
ere is also no requirement to alter diet or medication with the immunological FOBt, potentially increasing concordance.
is is supported by a meta-analysis performed by Vart et al, suggesting that the process involved in collection of the immunological test was perceived as more simple overall [27] , although it is likely that this may vary to some degree with the kit in question.
THE SENSITIVITY AND SPECIFICITY OF FAECAL OCCULT BLOOD TESTING AND ENDOSCOPY
Several recent articles have summarised the evidence behind screening using FOBts and compared immunological and guaiac approaches [2, 9, [14] [15] [16] [17] [18] [28] [29] [30] [31] . Traditionally, the guaiac test has delivered the highest combination of sensitivity, speci city and cost-e ciency [18] . It has therefore formed the basis of the majority of community screening programmes [32] , though with considerable variation in outcome [29] . Recent studies have highlighted improvements to the immunological test which have pushed it ahead of the guaiac test in terms of overall e cacy [28] [29] [30] [31] . A 2010 meta-analysis identi ed a comparative sensitivity and speci city of 67% and 85% for immunological FOBt compared to 54% and 80% for guaiac FOBt [28] . Increased participation rates and higher overall detection rates have also been noted [27, 28] . A cost-bene t analysis of immunological FOBt, performed by Wilschut et al, determined that biennial screening with a cut-o of 50ng/ml would prove most e cacious, at €14,000 per life year gained, for an asymptomatic population aged 55-75 [33] . e ability to quantify a FOB result potentially allows the establishment of a national cut-o level, localised adjustment of this gure in line with local healthcare funding priorities and greater potential for integration with alternative screening tools. Such a degree of subtlety is lacking in guaiac testing kits and, as a result, the UK Bowel Cancer Screening Programme (BCSP) has plans to introduce immunological testing kits forthwith [32] .
Nonetheless, there are major aws inherent in the essential modality of detecting FOB. Recent evidence suggests that sensitivity and positive predictive value of both quantitative and qualitative FOBts were much higher in men than women, while speci city and negative predictive value were substantially lower for men. Such data are only partly explained by sexrelated di erences in adenoma-carcinoma presentation [34] .
e risk of false results from such confounding factors as red meat intake, vegetables and vitamin C, might be mitigated to some extent by the use of immunological FOBt but some risk of false positive results remains from upper gastrointestinal sources of bleeding and around storage of the testing kits [8] . Moreover, a potential tumour must induce bleeding to be detected by an FOB test. is is a factor far more common in the mostly le -sided polypoid lesions which comprise approximately 85% of CRC [35] ; by implication omitting the other 15% of CRC which have a tendency towards a sessile phenotype and which are less likely to present with bleeding [36] . Right-sided cancers were more likely to have an abnormal J Gastrointestin Liver Dis, June 2014 Vol. 23 FOBt and be at a more advanced stage than le sided, when presenting to the UK BCSP [37] .
Colonoscopy and exible sigmoidoscopy (FS) have been widely examined as part of screening programmes and are frequently required for further investigation and treatment of any lesions identi ed through other means [2, 30, 38, 39] . Colonoscopy is currently the gold standard for both screening and treatment, though with little support from RCT data and variable outcomes in many studies, frequently dependent on the quality of the colonoscopy procedure [6, [40] [41] [42] . A recent meta-analysis of colonoscopy in an asymptomatic screening population identi ed an average sensitivity of 88.8%, with associated speci city of 75.4% [42] . Several back-to-back studies have shown an estimated colonoscopic miss-rate of between 20 and 25%, as well as identifying that 3-8% of patients with CRC had undergone a colonoscopy in the previous 3-5 years [43] . Flexible sigmoidoscopy has a yield of approximately 9.5% for large polyps and cancer [44] . Similar polyp miss rates have been noted with this procedure [45] . Nonetheless, its use as a stand-alone technique has been hampered by the limited colonic views obtained by the procedure and associated uncertainty over what ndings would necessitate proceeding to full colonoscopy [32] . ere is considerable debate regarding the bene t of full colonoscopy in reducing mortality from right sided cancer, compared to FS examination of the colon alone [35] . A large Canadian study did not note any reduction in mortality from right-sided CRC a er colonoscopy, though the screening colonoscopies were unidenti able [46] . By contrast, an examination of 10,124 consecutive screening colonoscopies by Imperiale et al identified 42% of advanced neoplasia proximal to the splenic exure [47] . Flexible sigmoidoscopy compares favourably with FOBts, when used as a stand-alone screening test, in terms of identi cation rate of large polyps and neoplasia [39] . A Cochrane systematic review identi ed a relative risk reduction of 0.85 for FS over FOBt [38] , whereas a recent large-scale randomised controlled trial (RCT) of oneo FS as a sole screening tool demonstrated a 33% reduced incidence of CRC and 43% reduced mortality [48] , data supported by other large prospective RCTs [49, 50] . Analysis of the optimum cost-e ciency in screening with guaiac FOBt and/or FS has shown the bene ts of a one-o FS at age 60, followed by biennial FOBt (+ colonoscopy if FOBt positive) at ages 61-70, with an estimated 22.7% reduction in CRC cases and 33.4% reduced deaths from CRC [51] . As a result, the UK BCSP has plans to o er a one-o FS at age 55 from 2013, in addition to the FOBt +/-colonoscopy already in place [2] .
ENDOSCOPY RELATED RISK
Endoscopy itself may be poorly tolerated and has several potentially major dangers, most notably perforation and haemorrhage post-polypectomy. Sedation or general anaesthetic and bowel preparation in at-risk individuals is also a source of risk. Risk of bowel perforation and haemorrhage has been estimated at between 0.1 and 0.25% for perforation and between 0.3% and 2.1% for bleeding [52] . However, such data is extremely variable according to location and study [6] . ese dangers are emphasised further when considering the numbers of individuals potentially exposed. For example, using the data produced by the US Multi-Society Task Force Risk, of 157 colonoscopies required to detect 1 cancer at worst this would expose 3.3 patients to perforation for each cancer detected [7] . However, in the UK BCSP, of 36,460 colonoscopies performed August 2006-2009 in the UK, a 0.09% perforation rate was noted, with major or intermediate bleeds noted at 0.13%, despite an approximately 50% polypectomy rate; no fatalities were noted [2, 6] . Several factors might account for regional variations in colonoscopy and FS complications, including the training and experience of the endoscopists, whether or not sedation was routinely used, the nature of sedation or general anaesthesia, the quality of bowel preparation, polypectomy rate and local prevalence of resectable lesions.
ECONOMIC COSTS OF GASTROINTESTINAL ENDOSCOPY
A three-round pilot study of screening as part of the UK BCSP identi ed a calculated cost of £5900 (€7000) per life-year saved [2] . Despite the unquestionable bene t of increased early identi cation of potential CRC in asymptomatic individuals [51] , higher detection rates also mean an increased burden on colonoscopic services [32] , though this might be alleviated to some extent by adjustment of the cut-o threshold in the FOBt, as suggested above, or adjustment of the colonoscopy training criteria, such as introducing screening certi cation as part of general endoscopic training for luminal gastroenterologists. Even a small increase in the positive FOBt rate might contribute to a signi cant increase in colonoscopic burden. For example, it has been estimated that "a sustained 2.5% positivity rate in an area with average acceptance rates will result in a 25% greater demand for colonoscopy in that screening centre compared with the national average" [32] . Endoscopy-based screening services are expensive to establish and maintain, at approximately £3000 (€3600) per quality-adjusted life-year (QUALY) [51] . us any re nement of the screening process might be nancially bene cial and, moreover, adjustment of screening criteria would allow improved coordination with local healthcare funding priorities. is might potentially involve a more complex risk stratifying model such as screening moderate risk with CT colonography (CTC, equal in sensitivity and speci city to optical colonoscopy if performed with the latest 3-D technology by speci cally-trained radiologists, though with a smaller risk of complications) [14, 15] , or a panel of biomarker tests in addition to, or in replacement, of FOBt.
ADJUVANT SCREENING TECHNOLOGIES
CT colonography, using the latest techniques, equipment and appropriately trained radiologists, has demonstrated a considerable improvement in sensitivity and speci city over the past 10 years. A 2005 meta-analysis shows sensitivity 85-93% and speci city of 97% for polyps and malignancy >1cm, though considerably less sensitive for smaller lesions [53] . By 2011, a meta-analysis could claim a superior sensitivity of 96.1% for cancer detection using CTC, compared to 94.7% for optical colonoscopy, suggesting diagnostic equivalence [41] ; the use of 3-D imaging was noted as particularly bene cial for the identi cation of early neoplastic change. Such diagnostic accuracy is not universally supported, particularly for lesions <6mm, however there does appear to be a broad consensus of the utility of this tool in screening [40] . e procedure is o en touted as less invasive, showing considerably lower risk of perforation (approximately 0.009% in one large multicentre study) [54] and reduced discomfort, despite CO 2 insu ation, compared to optical colonoscopy [55] . ough it must be considered that any polyps detected will require colonoscopic removal and the attendant risk attached to that procedure. For screening programmes speci cally, some studies have highlighted the bene t of a potential increase in uptake of screening due to patient preference for this test over colonoscopy [55, 56] ; though this is not supported in all studies [57] . Further bene ts include the potential for evaluating extracolonic organs, including staging any identi ed malignancy, and the possibility of avoiding bowel preparation through the use of faecal tagging [2] .
Two major drawbacks of this technique include radiation exposure and the cost of providing the service. A wide range of potential radiation doses have been reported depending on CT protocol used. However, there is a lack of clarity on the oncogenic risk attached to lower dose studies (<100mSv, typical CTC study radiation ranges 4.0-13.2 mSv) in particular, as well as in the role of iatrogenic radiation in sporadic cancer in the general population [58] . As yet, no epidemiological study has proven a link between low dose iatrogenic radiation exposure and risk of malignancy [58] . A recent risk-bene t analysis of CTC in an asymptomatic screening population identi ed a 0.15% risk of radiation-related malignancy for an average 50 year old undergoing the procedure every 5 years from age 50-80, including follow up scans required to investigate any potential extra-colonic ndings. Overall the risk was felt to be justi ed by the bene ts of early identi cation of malignancy [59] . Further developments in 3-D scanning, CT resolution and faecal tagging may assist with a reduction of associated risks by increasing sensitivity for small adenomas and other dysplastic tissues, thus reducing the number and interval of scans required. Economic cost is the other major hiccough in the use of CTC more generally in population screening for CRC. A 2012 meta-analysis of CTC use in screening identi ed that key determinants of cost-e ectiveness were the threshold for polyp referral for colonoscopic assessment and removal, or the inclusion of extra-colonic ndings [60] . Given that the risk of marked dysplasia and malignancy is thought to be less than 1% in polyps <6mm [60] , referral of only those polyps greater than this size and in su cient number would allow for an improvement in cost-e ectiveness in line with local screening and healthcare funding priorities. Unfortunately the study was inconclusive as to the overall cost-e ectiveness of CTC in a screening population [60] . A hypothetical model comparing 10-yearly CTC with biennial FOBt, 10-yearly FS and colonoscopy in asymptomatic screening population aged 60-69 identi ed increased cost-e ectiveness for CTC over optical colonoscopy, with the optical approach demonstrating an incremental cost per QUALY of £34,002 (€41,100) [61] . Although the above evidence has garnered considerable support from a wide variety of national guidelines as one potential option, it is mostly recommended for those unsuitable for colonoscopy in national screening programmes [26, 62] , rather than a stand-alone tool. is is in part due to insu cient evidence as to the exact role in the screening process, given that abnormalities o en require colonoscopic evaluation, the associated reduction in mortality and morbidity as well as the relative cost implications of integrating CTC into large-scale programmes. is includes a shi of the burden of screening cost from colonoscopy to radiology services [60] . Further clinical studies are underway to evaluate the potential in this technique [63, 64] .
e air-contrast barium enema is another imaging tool used to examine the bowel for neoplasia, especially for peri-surgical examination. It has previously been favoured for imaging the colon due to its high sensitivity for established cancer, low cost and few side e ects [65] . However, a 2005 prospective cohort study identi ed poor overall sensitivity (41%, compared to 55% and 98.7% for CTC and colonoscopy) and speci city (82%, 89% and 99.6%, respectively) for adenomatous lesions >6mm [66] . Although frequently mentioned, the barium enema does not now feature prominently in most population-level CRC screening guidelines.
FAECAL BIOMARKERS
e ideal biomarker will identify both high risk adenomas, which require excision, as well as established CRC, while excluding the normal bowel from further examination. It would function as a single "point of care" test which could guide therapeutic colonoscopy with a high degree of sensitivity and speci city, thus providing savings both in terms of risk to the patient and cost to the service provider. A marker correlated with TNM stage would aid scheduling of treatment. Diagnostic biomarkers for CRC are a popular area of research, using faeces as well as breath, blood, urine and tissue, focusing on three main categories of approach: cytogenetic methodology, protein assays and volatile organic metabolites (VOMs).
Faecal Cytogenetic Biomarkers
Colonocyte DNA is relatively simple to extract from faeces and has been the most successful basis for biomarker detection published to date. e majority of cytogenetic biomarkers have focused on identifying characteristic genomic and epigenetic changes present in CRC, through isolation and assessment of tumour-related DNA from faeces and blood (serum and plasma). To a lesser extent investigation of miRNA thought to be connected to tumour cells has also borne fruit. Panels of methylated genes such as: APC, ATM, hMLH1, SFRP2, HLTF, MGMT, GSTP1 or VIMENTIN have been frequently examined independently or in combination with mutation markers such as APC, k-ras, p53 and BAT-23, with variable sensitivity and speci city [67] .
Two recent meta-analyses have examined the potential for using faecal DNA markers in the diagnosis of CRC [67, 68] . Luo et al used methylation markers alone to calculate a mean sensitivity of 62% and 89% speci city for detection of CRC and 54% and 88% respectively for adenoma [68] . Yang and colleagues examined the literature on methylation and mutation markers in a slightly di erent way: looking for potential risk strati cation. ey identi ed a sensitivity of 68% and speci city of 93% for CRC and 33% sensitivity and 94% speci city for high risk adenomas but no signi cant identification of moderate risk subgroups of either [67] . Methylation markers were identi ed as more sensitive but less speci c than mutation markers [67] . e most promising panel of tests shows the utility of a combined approach, measuring BMP3, NDRG4, vimentin and TFPI2, with mutant KRAS and α-actin. A blinded, multi-centre case-control study identi ed 85% of samples with CRC and 54% with adenomas >1cm, to a speci city of 90%. Detection rates did not vary with site of tumour and were greatly increased for larger adenomas (>4cm, 92%) [69] . An assay of faecal methylated VIMENTIN (ColoSure™) has been introduced as a commercial test. Simultaneous measurement of methylated Vimentin and DNA integrity in faecal samples demonstrated 87.5% sensitivity and 82% speci city [70] . However, faecal DNA measurements remain less cost-effective than current population-based screening methods, partly due to high individual cost [71] .
MicroRNAs (miRNAs), a putatively more stable corollary of mRNA, are another extractable neoplasia-related stool biomarker. A comprehensive review of the subject has been published recently in this journal [72] . Faecal miRNAs have achieved similar e cacy for immunochemical FOBts [72] . For example, stool miR-106a demonstrated a sensitivity of 34.2% and speci city of 97.2% which, when combined with an immunological FOBt, improved to 70.9% and 96.3%, respectively [73] . Other reasonable biomarkers include miR-135 (46.2% sensitivity, 95% speci city) [74] and miR-144 (74% sensitivity, 84% speci city) [75] . Again, relative cost implications and the current lack of research in this speci c area precludes their use in screening in the short term, while potentially leaving them as an option for future testing, most likely as part of a panel of cytogenetic markers.
Faecal Protein-based Biomarkers
e low sensitivity of FOBt has also led to an increased interest in the identi cation of alternative biomarkers found in stool. Transferrin has been quanti ed as a representation of faecal haemoglobin, because of its comparatively increased stability in samples. However, even when combined with both immunological and guaiac FOBt, only 76.5% and 88.2% sensitivity, respectively, was achieved for detecting both CRC and pre-cancerous lesions, with a speci city of 64.3% and 48.7%. In the same sample group, the immunological FOBt achieved 69.4% and 75.5% sensitivity and speci city for identi cation of both types of lesions combined [28] . Tumour M2-PK is the dimeric form of the M2 isoenzyme of pyruvate kinase, which is thought to be characteristic of tissues which are undergoing neoplastic change [5] . A meta-analysis of faecal M2-PK levels by Tonus et al compared guaiac and immunological FOBt, demonstrating a mean sensitivity of 80.3% with speci city of 95.2% for M2-PK (compared to guaiac FOBt with 13%-50% sensitivity and 7.3%-20% for immunological FOBt) [5] . As might be expected from the nature of the biomarker, M2-PK scored particularly highly when detecting early adenomas, compared to both guaiac FOBt and immunological FOBt [5] , though some other studies have not re ected this trend [76] . A further recent meta-analysis summarised with a sensitivity of 79% and speci city of 81% [77] .
Measurements of neutrophil-related markers have also proved popular, with studies involving faecal calprotectin, calgranulin B (a heterodimer of calprotectin) and lactoferrin [78] [79] [80] [81] . However, such studies have re ected a lack of speci city for colorectal neoplasia, even in comparison to guaiac FOBt, partially due to their strong link with colonic in ammation [82] . Other tumour-related proteins such as minichromosome maintenance protein (MCM2), carcinoembryonic antigen (CEA), decay-accelerating factor (DEA) and clusterin have also been investigated in small-scale studies for potential screening use, with varying sensitivity and speci city [83] [84] [85] [86] , though as yet none appear to o er considerable improvement over FOBt.
Faecal Metabolomics
Techniques which seek to measure the metabolome of the gut have recently garnered interest as a method of characterising the complex interaction between the microbiome and host cells in both disease and health. ese approaches can identify metabolic changes associated with di erent disease states [87, 88] . Volatile organic compounds (VOCs) released from faeces, breath, serum, urine and the tissues themselves can be evaluated as an assessment of the volatile organic metabolome (VOM). The identification of a specific "odour-print" associated with disease as a screening tool either by machine or using the canine nose has demonstrated impressive sensitivity and speci city [89, 90] . Several studies have attempted to correlate VOCs with various colorectal samples. In a broad approach, using an electronic nose, De Meij and colleagues analysed a total of 157 stool samples (40 with CRC, 60 with advanced adenomas and 57 healthy controls), identifying a sensitivity and speci city of 85% and 87%, respectively for CRC, together with those of advanced adenomas, though with reduced sensitivity of 62%, speci city 86% [91] . However, many of the established techniques for VOM measurement in stool remain as "proof of concept" studies and have not yet been validated in large clinical cohorts. For example, Monleon et al explored the constituents of faecal water using an NMRbased approach. Although not speci cally geared to establish faecal water analysis as a screening tool, it did identify a signi cant reduction in short chain fatty acid levels (butyrate and acetate) in CRC patient stool compared to control [92] . Sonoda et al utilised speci cally trained dogs to identify the stool of patients with colorectal cancer, with a sensitivity of 97% and speci city of 99% [93] . However, this was examined in only 37 samples and such success has proven di cult to replicate in other studies using di erent dogs, odour material and other types of cancer [94] . Further studies are required in this area to evaluate the myriad of potential connections between the VOM, as detectable in stool, blood, breath and urine, and colorectal neoplasia.
CONCLUSIONS
Many countries maintain successful screening programmes for colorectal cancer. At a population level many of these involve a combination of FOB testing and colonoscopy. However the sensitivity and speci city of current screening modalities remain clinically suboptimal, exposing patients to risk of harm and the screening services to increased cost. screening methodology has been identi ed as clearly more cost-e ective than any other [95] . e key step in achieving maximum e ciency from population screening appears to be in the uptake of the test. us a shi from guaiac FOBt to immunological FOBt, with the associated improvement in acceptability to the patient, appears to be an important initial step, together with improved patient education about the purpose and nature of the screening and increased options for further investigation. However, ideally, a more acceptable and more accurate test would be employed instead or concurrently to reduce the number of colonoscopies required. Increased integration of CTC services into population screening appears to be a potentially promising approach. is could be done by further risk strati cation, either using the immunological FOBt itself, through risk modelling for such factors as risk of right sided malignancy or as a method of investigating those "intermediate" risk FOBs which would usually require repeated FOB testing immediately. A low risk individual, positive for FOB, might be o ered CTC in preference to colonoscopy. Several stool-based tests appear to have potential for improving diagnostic efficiency. Faecal sDNA panels demonstrate impressive sensitivity and speci city, especially when combined with immunological FOBt. However, sDNA testing remains considerably more expensive than immunological FOBt when used as a screening tool and appears no more acceptable when the practicalities of sampling are taken into consideration. Faecal M2-PK also appears promising, particularly in the detection of early neoplasia, though again, it is more expensive than immunological FOBt and is likely to have a similar uptake from the screening population. Faecal VOM measurement also may have a role to play, although studies have not demonstrated signi cant validity in large patient groups.
Overall, a multi-layered risk stratification approach, hypothetically integrating FOBt and both serum and faecal biomarkers such as M2-PK and sDNA, to determine e ectively who could be o ered CT colonography and who ought to proceed straight to optical colonoscopy, could potentially be combined with a risk-prediction algorithm to improve the e ciency of the programme further [96, 97] .
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